Letter

Dose adjustment in renal impairment: Response from the British National Formulary

BMJ 2005; 331 doi: 10.1136/bmj.331.7511.292 (Published 28 July 2005)
Cite this as: BMJ 2005;331:292.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Dinesh K Mehta, executive editor (dmehta@bnf.org)
  1. British National Formulary, Royal Pharmaceutical Society of Great Britain, London SE1 7JN

    EDITOR—Vidal et al are rightly concerned that information on dose adjustment is not as well supported by evidence as our knowledge about the effectiveness of modern interventions (p 263). 1 But, as they have found, the lack of robust data to guide clinicians on the precautions to take when using drugs is woeful. Therefore, their conclusions come as no surprise to compilers of drug information.


    Embedded Image

    Because there are few accessible studies on dose adjustment in renal impairment, the British National Formulary (BNF) has to rely on summaries of product characteristics, which reflect data submitted for gaining marketing …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular